Highlights:
• Progression Free Survival (PFS) Hazard Ratio improvement for eftilagimod alpha (efti) group versusplacebo at the 6-month landmark
• Increased Overall Response Rate (ORR) of 48.3% in the efti group versus 38.4% in the placebo group
• Immutep will advance discussions with regulatory authorities regarding the next clinical developmentsteps for efti
• Global webcast at 8am AEDT on Thursday March 26th / 5pm US EDT on Wednesday March 25th,webcast details below
For more information, please download the attached PDF
Download this document
